Market closed

Oric Pharmaceuticals/$ORIC

Oric Pharmaceuticals shares are trading higher after the company presented preclinical data at a conference, highlighting the potential of ORIC-944 as a PRC2 inhibitor for prostate cancer treatment.
7 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Oric Pharmaceuticals

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Ticker

$ORIC
Trading on

Industry

Biotechnology

Employees

115

ORIC Metrics

BasicAdvanced
$362M
-
-$1.83
1.20
-
$362M
1.2
$14.67
$3.90
833K
10.555
10.302
2.539
3.849
-33.95%
-54.73%
1.49
1.49
-3.117
-6.32%
-4.02%

What the Analysts think about ORIC

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Oric Pharmaceuticals stock.

ORIC Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ORIC Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ORIC

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Oric Pharmaceuticals stock?

Oric Pharmaceuticals (ORIC) has a market cap of $362M as of April 30, 2025.

What is the P/E ratio for Oric Pharmaceuticals stock?

The price to earnings (P/E) ratio for Oric Pharmaceuticals (ORIC) stock is 0 as of April 30, 2025.

Does Oric Pharmaceuticals stock pay dividends?

No, Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders as of April 30, 2025.

When is the next Oric Pharmaceuticals dividend payment date?

Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders.

What is the beta indicator for Oric Pharmaceuticals?

Oric Pharmaceuticals (ORIC) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.